All In Biotech

Drug Trial Radar · NCT07791524

Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of MWN109 Tablet in Non-Diabetic Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Jan 5, 2026

Primary completion

Jul 9, 2026

Study completion Jul 9, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants with overweight or obesity. Approximately 240 participants will be enrolled. All participants will be stratified by gender (male or female) and then randomized 1:1:1:1:1 to 5 treatment groups, with approximately 48 participants per group. All treatment groups will implement dose titration to achieve the target dose. This study consists of a screening period of up to 2 weeks, a treatment period of 20 weeks, and a follow-up period of 2 weeks, totaling 24 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 20 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 20 weeks of treatment, as well as the change in waist circumference relative to the baseline.

Conditions

  • Overweight , Obesity

Interventions

  • MWN109 1Drug

    Administered orally, QD, 20 weeks

  • MWN109 2Drug

    Administered orally, QD, 20 weeks

  • MWN109 3Drug

    Administered orally, QD, 20 weeks

  • MWN109 4Drug

    Administered orally, QD, 20 weeks

  • PlaceboDrug

    Administered orally, QD, 20 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight compared to baseline after 20 weeks of drug administrationTime frame: Baseline, week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.